Moving on from a major setback, Roche lines up a new Huntington's program for gene therapy sub Spark
Undaunted by a severe setback on Huntington’s disease earlier this year, Roche has headed straight back into the fray. Only this time, they’re adding to a slate of new tie-ups for their gene therapy subsidiary Spark.
Spark announced this morning that they will collaborate with US biotech NeuExcell to develop a gene therapy for patients suffering from HD. As part of an agreement between the two companies, Spark will have access to NeuExcell’s gene therapy platform, and NeuExcell’s research team will work with Spark to advance the program.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.